---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-019558"
form_type: "8-K"
ticker: "PULM"
cik: "0001574235"
company_name: "Pulmatrix, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:04:18.249228+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pulmatrix Phase 1 data for inhaled DHE (PUR3100) published: rapid absorption, better tolerability vs IV DHE

## Summary
- All PUR3100 doses showed mean Cmax above 1000 pg/mL efficacy threshold; Tmax 5 min vs 5.5 min for IV DHE.
- Lower incidence of nausea (21% vs 86%), vomiting (0% vs 29%), and headache (16% vs 57%) compared to IV DHE.
- Data published in Headache: The Journal of Head and Face Pain; FDA allowed Phase 2 study to proceed.
- Company seeking financing or partnership to advance PUR3100 into Phase 2 for acute migraine.

## SEC filing metadata
- accession: 0001493152-24-019558
- form_type: 8-K
- ticker: PULM
- cik: 0001574235
- company_name: Pulmatrix, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574235/000149315224019558/0001493152-24-019558-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574235/000149315224019558/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-019558
- JSON: https://secwatch.observer/filing/0001493152-24-019558.json
- Plain text: https://secwatch.observer/filing/0001493152-24-019558.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.